560 filings
Page 6 of 28
8-K
MBRX
Moleculin Biotech Inc
18 Apr 23
Sponsored research data presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023
1:35pm
DEFA14A
MBRX
Moleculin Biotech Inc
13 Apr 23
Additional proxy soliciting materials
7:18am
DEF 14A
MBRX
Moleculin Biotech Inc
Definitive proxy
13 Apr 23
7:00am
8-K
MBRX
Moleculin Biotech Inc
3 Apr 23
Regulation FD Disclosure
7:00am
PRE 14A
MBRX
Moleculin Biotech Inc
Preliminary proxy
3 Apr 23
6:01am
8-K
MBRX
Moleculin Biotech Inc
23 Mar 23
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
8:20am
8-K
MBRX
Moleculin Biotech Inc
22 Mar 23
Regulation FD Disclosure
4:20pm
10-K
2022 FY
MBRX
Moleculin Biotech Inc
Annual report
22 Mar 23
4:15pm
8-K
MBRX
Moleculin Biotech Inc
15 Mar 23
Regulation FD Disclosure
8:30am
8-K
MBRX
Moleculin Biotech Inc
13 Mar 23
Moleculin Announces it Has No Exposure to Silicon Valley Bank Situation
7:05am
8-K
MBRX
Moleculin Biotech Inc
9 Mar 23
Regulation FD Disclosure
8:35am
8-K
MBRX
Moleculin Biotech Inc
1 Mar 23
Regulation FD Disclosure
8:45am
8-K
MBRX
Moleculin Biotech Inc
13 Feb 23
Regulation FD Disclosure
8:11am
8-K
MBRX
Moleculin Biotech Inc
8 Feb 23
Regulation FD Disclosure
5:00pm
8-K
MBRX
Moleculin Biotech Inc
3 Feb 23
Termination of a Material Definitive Agreement
5:20pm
8-K
MBRX
Moleculin Biotech Inc
21 Dec 22
Regulation FD Disclosure
8:25am
8-K
MBRX
Moleculin Biotech Inc
15 Dec 22
Preliminary efficacy updated to 80% overall response rate (ORR) demonstrated in single agent AML trial following database lock
8:37am
8-K
MBRX
Moleculin Biotech Inc
7 Dec 22
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
8:45am
4
Klemp Walter V
28 Nov 22
Moleculin Biotech / WALTER V KLEMP ownership change
6:00pm
4
Klemp Walter V
23 Nov 22
Moleculin Biotech / WALTER V KLEMP ownership change
8:30am